Document is current
Any future updates will be listed below
-
Authors
Fix, Samantha M https://orcid.org/0000-0002-1608-4646
Forget, Marie-Andrée
Sakellariou-Thompson, Donastas https://orcid.org/0000-0001-5954-9557
Wang, Yunfei
Griffiths, Tamara M https://orcid.org/0000-0002-4597-308X
Lee, Minjung https://orcid.org/0000-0001-5499-044X
Haymaker, Cara L https://orcid.org/0000-0002-1317-9287
Dominguez, Ana Lucía
Basar, Rafet
Reyes, Christopher
Kumar, Sanjay
Meyer, Larissa A https://orcid.org/0000-0002-2687-7463
Hwu, Patrick https://orcid.org/0000-0002-8293-1313
Bernatchez, Chantale https://orcid.org/0000-0001-5926-3460
Jazaeri, Amir A
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03610490 at ClinicalTrials.govnct03610490 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
https://doi.org/10.1136/jitc-2023-006822
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes
https://doi.org/10.1136/jitc-2021-003082
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
https://doi.org/10.1136/jitc-2021-003750
An update on emerging drugs in osteosarcoma: towards tailored therapies?
https://doi.org/10.1080/14728214.2019.1654455
nct03449108 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
https://doi.org/10.1136/jitc-2023-006822
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes
https://doi.org/10.1136/jitc-2021-003082
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
https://doi.org/10.1136/jitc-2021-003750
An update on emerging drugs in osteosarcoma: towards tailored therapies?
https://doi.org/10.1080/14728214.2019.1654455
nct01740557 at ClinicalTrials.govDocuments that mention this clinical trial
1338 Multi-cohort phase II study of autologous centrally manufactured tumor infiltrating lymphocytes
https://doi.org/10.1136/jitc-2025-sitc2025.1338
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
https://doi.org/10.1136/jitc-2021-003750
nct01955460 at ClinicalTrials.govDocuments that mention this clinical trial
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
https://doi.org/10.1136/jitc-2021-003750
CARs are sharpening their weapons
https://doi.org/10.1136/jitc-2023-008275
nct01955460 at ClinicalTrials.govDocuments that mention this clinical trial
172 Overcoming immunosuppressive TGF-β signaling in human ovarian cancer-derived tumor infiltrating lymphocytes via non-viral CRISPR engineering
https://doi.org/10.1136/jitc-2021-sitc2021.172
340 TGFβDNRII genetically-engineered TIL: characterizing final drug product from a phase I clinical trial
https://doi.org/10.1136/jitc-2023-sitc2023.0340
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
https://doi.org/10.1136/jitc-2021-003750
Documents that mention this clinical trial
172 Overcoming immunosuppressive TGF-β signaling in human ovarian cancer-derived tumor infiltrating lymphocytes via non-viral CRISPR engineering
https://doi.org/10.1136/jitc-2021-sitc2021.172
340 TGFβDNRII genetically-engineered TIL: characterizing final drug product from a phase I clinical trial
https://doi.org/10.1136/jitc-2023-sitc2023.0340
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
https://doi.org/10.1136/jitc-2021-003750
-
Funding
Funding for this research was provided by:
Dunwoody-Edwards-Reese Ovarian Cancer Philanthropic Fund
National Institutes of Health (F32CA253968)
National Institutes of Health (K07CA201013)
National Institutes of Health (P30CA016672)
National Institutes of Health (TL1TR003169)
Miriam and Jim Mulva Research Fund
CPRIT Research Training Program (RP170067)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- License Information
